Search results
Showing 646 to 660 of 855 results for end of life
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
This quality standard covers care for adults before, during and after primary elective hip, knee or shoulder joint replacement. It describes high-quality care in priority areas for improvement. It does not cover joint replacement as treatment for primary or secondary cancer affecting the bones.
View quality statements for QS206Show all sections
Sections for QS206
- Quality statements
- Quality statement 1: Preoperative rehabilitation advice for hip and knee replacement
- Statement 2: Choice between partial and total knee replacement
- Statement 3: Tranexamic acid during hip and knee replacement
- Quality statement 4: Preventing implant selection errors
- Statement 5: Postoperative rehabilitation
- Update information
- About this quality standard
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Molecular testing strategies for Lynch syndrome in people with colorectal cancer (HTG430)
Evidence-based recommendations on using immunohistochemistry or microsatellite instability testing to guide further testing for Lynch syndrome in people with colorectal cancer.
with a confirmed diagnosis of idiopathic pulmonary fibrosis. Appropriate end points may include mortality (allcause and idiopathic...
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults.
Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (HTG423)
Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease in adults.
Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
View recommendations for TA340Show all sections
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
This guideline sets out an antimicrobial prescribing strategy for adults with leg ulcer infection. It aims to optimise antibiotic use and reduce antibiotic resistance.
Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)
This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.